Commentary

Podcast

Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong

Author(s):

Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.

At the end of 2022, adagrasib received its first FDA approval for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer. Research is ongoing into adagrasib, a KRAS G12 inhibitor, for other tumors.

In today’s episode, we are joined by Jun Gong, MD, associate professor of medicine and the medical director of colorectal cancer in the Division of Medical Oncology at Cedars-Sinai Medical Center. During this interview, he discusses the mechanism of adagrasib, what other diseases it is being studied in, the latest data on adagrasib in colorectal cancer, and the importance of conducting genomic testing.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Mansi Shah, MD
Dr John Mascarenhas
5 experts are featured in this series
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
CK Wang, MD, COTA
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo